Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capricor TherapeuticsCAPR +1.29%24 Cash-to-Debt is 2.61 as of Jun. 2026, which is 93% below its 10-year median of 36.74. GuruFocus rates CAPR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,398 Biotechnology companies, Capricor Therapeutics ranks worse than 63.52% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Capricor Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.61.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Capricor Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Capricor Therapeutics's Cash-to-Debt or its related term are showing as below:
CAPR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84 Med: 36.74 Max: No Debt
Current: 2.61
During the past 13 years, Capricor Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.84. And the median was 36.74.
CAPR's Cash-to-Debt is ranked worse than 63.52% of 1398
companies
in the Biotechnology industry
Industry Median: 6.68
vs CAPR: 2.61
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Capricor Therapeutics Cash-to-Debt Related Terms
Capricor Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Capricor Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Capricor Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics (CAPR) has a Cash-to-Debt of 2.61 as of Jun. 2026. This is 93% below median its historical median of 36.74. Over the past decade, Capricor Therapeutics' Cash-to-Debt has ranged from 0.84 to 10,000.00. According to the industry distribution chart, Capricor Therapeutics ranks #888 out of 1398 companies in the Biotechnology industry, placing it in the top 63.5%.
Is Capricor Therapeutics' Cash-to-Debt too high?
Capricor Therapeutics' current Cash-to-Debt of 2.61 is 93% below median its 10-year median of 36.74. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.68. Capricor Therapeutics' value of 2.61 is 60.9% below this industry median. Based on the distribution chart, Capricor Therapeutics ranks #888 out of 1398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Capricor Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Cash-to-Debt compare to BLSM and ZURA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #888 out of 1398 companies for Cash-to-Debt. This places Capricor Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.68. Capricor Therapeutics' value of 2.61 is 60.9% below this benchmark. Historically, Capricor Therapeutics' own Cash-to-Debt has ranged from 0.84 to 10,000.00 over the past decade. While the company's 10-year median is 36.74 vs. the industry median of 6.68, Capricor Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.68, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Capricor Therapeutics's current Cash-to-Debt of 2.61 is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current Cash-to-Debt is 2.61, which is 93% below median its own 10-year median of 36.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (CAPR) has a current Cash-to-Debt of 2.61. The current Cash-to-Debt is 2.61, which is 93% below median its 10-year median of 36.74 and 60.9% below the Biotechnology industry median of 6.68. Capricor Therapeutics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Cash-to-Debt is 2.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
24GF Score
Get the complete analysis for CAPR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
